Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy.

Abstract:

:Abstract The aim of this study was to evaluate the prognostic importance of rituximab and radiotherapy in patients with primary mediastinal large B-cell lymphoma (PMBCL) receiving doxorubicin-containing chemotherapy. Seventy-nine patients with PMBCL received CHOP chemotherapy with (n = 39) or without rituximab (n = 40), and 60 patients received additional radiotherapy. Patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) had significantly superior survival rates. The 5-year overall survival (OS) and progression-free survival (PFS) rates were 83.7% and 76.7% for R-CHOP, compared with 48.3% (p = 0.011) and 44.2% (p = 0.012) for CHOP, respectively. Similarly, the 5-year OS and PFS rates for early stage patients were 93.8% and 84.6% with R-CHOP, and 52.0% (p = 0.002) and 46.6% (p = 0.003) with CHOP, respectively. Patients treated with chemotherapy and radiotherapy had better survival and local control (LC) rates compared with chemotherapy alone. The 5-year OS, PFS and LC rates for early stage patients were 73.6%, 69.9% and 92.6% for chemotherapy and radiotherapy, and 50.8% (p = 0.076), 36.9% (p = 0.008) and 56.4% (p < 0.001) for chemotherapy alone, respectively. Early stage patients treated with R-CHOP and radiotherapy had 5-year OS, PFS and LC rates of 96.4%, 85.9% and 93.1%. R-CHOP plus consolidation radiotherapy was associated with excellent survival and LC rates.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Xu LM,Fang H,Wang WH,Jin J,Wang SL,Liu YP,Song YW,Ren H,Zhou LQ,Li YX

doi

10.3109/10428194.2012.746684

subject

Has Abstract

pub_date

2013-08-01 00:00:00

pages

1684-90

issue

8

eissn

1042-8194

issn

1029-2403

journal_volume

54

pub_type

杂志文章
  • Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival.

    abstract::We compared bcl-2 with P-glycoprotein expression (C494 and JSB1), and both with ex vivo chemosensitivity by Differential Staining Cytotoxicity (DiSC) assay (25 cytotoxic drugs), in 76 fresh haematological specimens, including 51 chronic lymphocytic leukaemias (CLL). Strong correlations were seen between bcl-2 and Pgp ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609045722

    authors: Bosanquet AG,Bell PB,Burlton AR,Amos TA

    更新日期:1996-12-01 00:00:00

  • Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).

    abstract::The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709039047

    authors: Montillo M,Tedeschi A,Centurioni R,Leoni P

    更新日期:1997-05-01 00:00:00

  • Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.

    abstract::Along with the establishment of more intense chemotherapeutic regimens including fludarabine for the treatment of indolent lymphoproliferative diseases like chronic lymphocytic leukemia (CLL), an increasing amount of cases with progressive multifocal leukoencephalopathy (PML) due to JC virus have been observed. We rep...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000116625

    authors: Kiewe P,Seyfert S,Körper S,Rieger K,Thiel E,Knauf W

    更新日期:2003-10-01 00:00:00

  • Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.

    abstract::Impressive gains have been made in the therapy of childhood acute lymphoblastic leukemia (ALL) in recent years such that remissions today are commonly achieved in up to 95% of patients and long term disease-free survival rates approach 70%. Methotrexate is a key component in ALL consolidation and maintenance therapies...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609093433

    authors: Matherly LH,Taub JW

    更新日期:1996-05-01 00:00:00

  • Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?

    abstract::T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoproliferative disorder with distinctive clinical and laboratory features. It is often resistant to conventional chemotherapy, but complete or partial responses have been documented with the use of purine analogues. We report on two cases of T-PLL with a slightly d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000040035

    authors: Delgado J,Bustos JG,Jimenez MC,Quevedo E,Hernandez-Navarro F

    更新日期:2002-12-01 00:00:00

  • The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.

    abstract::Abstract ATM gene alteration is a frequent event in pathogenesis of chronic lymphocytic leukemia (CLL) and occurs as monoallelic loss in the form of 11q23 deletion, with and without mutation in the remaining ATM allele. ATM is a principal DNA damage response gene and biallelic ATM alterations lead to ATM functional lo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.829919

    authors: Stankovic T,Skowronska A

    更新日期:2014-06-01 00:00:00

  • Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies.

    abstract::To better define the incidence and nature of secondary chromosome anomalies in mantle cell lymphoma (MCL) carrying the t(11:14)/BCL1 rearrangement, cytogenetic and fluorescence in situ hybridization studies (FISH) were performed in 42 patients (39 classical histology, 3 blastoid variant), using 6q21, 9p21/p16, 13q14, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097656

    authors: Bigoni R,Cuneo A,Milani R,Roberti MG,Bardi A,Rigolin GM,Cavazzini F,Agostini P,Castoldi G

    更新日期:2001-02-01 00:00:00

  • Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).

    abstract::Patients with CTCL are at increased risk for bacteremia which is a leading cause of morbidity and mortality. We assessed risk factors for and the impact of bacteremia on survival in a retrospective cohort of 188 CTCL patients at a single US academic institution treated between 1990 and 2018. With a median follow up of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1779259

    authors: Allen PB,Switchenko J,Ayers A,Kim E,Lechowicz MJ

    更新日期:2020-11-01 00:00:00

  • Morphologic features of binucleated lymphocytes to assess the diagnosis of persistent B-cell polyclonal lymphocytosis or other mature B-cell neoplasms.

    abstract::The observation of binucleated lymphocytes (BNLs) on a peripheral blood smear is essential to the diagnosis of persistent polyclonal B-cell lymphocytosis (PPBL). Only a few case reports have mentioned their presence in other contexts, mainly mature B-cell neoplasms such as chronic lymphocytic leukemia or reactive circ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.843680

    authors: Lesesve JF,Gressot AL,Troussard X,Mossafa H,Cornet E

    更新日期:2014-07-01 00:00:00

  • Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

    abstract::The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1824069

    authors: Segman Y,Ribakovsky E,Avigdor A,Goldhecht Y,Vainstein V,Goldschmidt N,Harlev S,Horwitz N,Gutwein O,Gurion R,Itchaki G,Abadi U,Nemets A,Sofer O,Zektser M,Tadmor T,Dally N,Filanovsky K,Leiba M,Sarid N,Benyamini N,

    更新日期:2021-01-01 00:00:00

  • CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.

    abstract::Platelet/endothelial cell adhesion molecule 1 (PECAM-1, CD31) is an immunoglobulin superfamily member expressed on the surface of platelets, leukocytes and endothelial cells. The role of CD31 in biology of lymphomas has not yet been systemically studied. Expression of cell surface CD31 was analyzed by flow cytometry o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1849678

    authors: Vockova P,Molinsky J,Klanova M,Karban J,Spacek M,Havranek O,Kupcova K,Kazantsev D,Trneny M,Klener P

    更新日期:2020-11-25 00:00:00

  • Inhibition of GM-CSF production by recombinant human interleukin-4: negative regulator of hematopoiesis.

    abstract::Interleukin-4 (IL-4), also known as B-cell stimulatory factor-1 (BSF-1), was initially identified as a T-cell product that mediates anti-IgM-induced DNA synthesis in B-lymphocytes. Various aspects of this highly pleiotropic cytokine have been described, including those on hematopoietic progenitor cells. However, the r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509059661

    authors: Sawada K,Sato N,Koike T

    更新日期:1995-09-01 00:00:00

  • Lack of involvement of T-lymphocytes in the leukaemic population during prolonged chronic phase of Philadelphia chromosome positive chronic myeloid leukaemia.

    abstract::Nine patients with prolonged (> 2 years) chronic phase chronic myeloid leukaemia (CML) were investigated for the presence of T-cell involvement in the leukemic clone. Pure populations of peripheral blood T-cell populations were obtained by culturing separated mononuclear cells in the presence of pokeweed mitogen and I...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309145886

    authors: Ariad S,Dajee D,Willem P,Bezwoda WR

    更新日期:1993-06-01 00:00:00

  • Rapid Remission Induction and Improved Disease Free Survival in Acute Myeloid Leukaemia Using Daunorubicin, ARA-C, and CCNU.

    abstract::Thirty-four patients with acute myeloblastic leukaemia were treated with DAC, a schedule containing the nitrosourea CCNU (lomustine) 200 mg/m2 given on day one of treatment, together with a standard "3 + 7" remission induction schedule of daunorubicin (DR) and cytosine arabinoside (Ara-C). The results were compared wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009050988

    authors: Barrett AJ,Treleaven JG,Samson DM,Evans M,Gaminara E,Foadi M,McCarthy DM

    更新日期:1990-01-01 00:00:00

  • Non-Hodgkin lymphoma in Chile: a review of 207 consecutive adult cases by a panel of five expert hematopathologists.

    abstract::The distribution of subtypes of non-Hodgkin lymphoma (NHL) in Latin America is not well known. This Chilean study included 207 consecutive cases of NHL diagnosed at five cancer centers in the capital, Santiago, and one center in Viña del Mar. All cases were reviewed and classified independently by five expert hematopa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,评审

    doi:10.3109/10428194.2012.654471

    authors: Cabrera ME,Martinez V,Nathwani BN,Muller-Hermelink HK,Diebold J,Maclennan KA,Armitage J,Weisenburger DD

    更新日期:2012-07-01 00:00:00

  • Growth control mechanisms in multiple myeloma.

    abstract::Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809050906

    authors: Hawley RG,Berger LC

    更新日期:1998-05-01 00:00:00

  • Diagnostic imaging in the evaluation of renal lymphoma.

    abstract::Renal lymphoma usually is a manifestation of disseminated disease and often is asymptomatic. Occasionally, the kidney(s) may be the major or only demonstrable site of disease, which may then present with a variety of urologic symptoms. The imaging studies should be tailored according to the presenting symptoms and pri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409114138

    authors: Eisenberg PJ,Papanicolaou N,Lee MJ,Yoder IC

    更新日期:1994-12-01 00:00:00

  • Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

    abstract::Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2016.1161185

    authors: Goebeler ME,Bargou R

    更新日期:2016-05-01 00:00:00

  • High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.

    abstract::Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children. Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately. Scarce information is available about pediatric NLPHL tre...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600573291

    authors: van Grotel M,Lam KH,de Man R,Beishuizen A,Pieters R,van den Heuvel-Eibrink MM

    更新日期:2006-08-01 00:00:00

  • Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

    abstract::Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.803226

    authors: Brown JR

    更新日期:2014-02-01 00:00:00

  • Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours.

    abstract::HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701760011

    authors: Burke LP,Kukoly CA

    更新日期:2008-02-01 00:00:00

  • High dose cyclophosphamide: stem cell mobilizing capacity in 21 patients.

    abstract::In the present study we assess the antitumor effect and circulating stem cells (CSC) mobilizing capacity of high-dose cyclophosphamide (5 to 7 gr/m2, HDCY). This treatment was given to 21 patients with various hematologic malignancies (8 NHL, 5 MM, 4 HD, 3 CML) excluding 1 with neuroblastoma. All were eligible for lat...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199409049652

    authors: Indovina A,Majolino I,Scimè R,Vasta S,Gentile S,Liberti G,Santoro A,Pampinella M,Caronia F

    更新日期:1994-06-01 00:00:00

  • Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.

    abstract::We conducted a phase I clinical trial of a new combination of fludarabine and paclitaxel in which 19 patients with histologically confirmed recurrent low-grade non-Hodgkin's lymphoma (NHL) were treated at five dose levels. Fludarabine was administered intravenously by bolus for 5 days and paclitaxel was given by intra...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709109160

    authors: Younes A,Rodriguez MA,McLaughlin P,North L,Sarris AH,Pate O,Hagemeister FB,Romaguera J,Preti A,Bachier C,Cabanillas F

    更新日期:1997-06-01 00:00:00

  • CD105 (endoglin) expression on hematopoietic stem/progenitor cells.

    abstract::Endoglin (CD105) is a component of the transforming growth factor-beta (TGF-beta) receptor (TGF-betaR) complex. Together with betaglycan, CD105 is considered as a TGF-betaR accessory molecule (also called TGF-betaRIII), but its functions in the receptor-ligand interactions are still poorly understood. A small subset o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109097744

    authors: Pierelli L,Bonanno G,Rutella S,Marone M,Scambia G,Leone G

    更新日期:2001-11-01 00:00:00

  • Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.

    abstract::Matrix high-throughput screening (HTS) methods are increasingly employed to rapidly define potential therapeutic drug combinations. We used combination HTS to identify compounds showing synergistic anti-proliferative activity with ibrutinib, an irreversible, small-molecule inhibitor of Bruton's tyrosine kinase. The go...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1349899

    authors: Schaffer M,Chaturvedi S,Davis C,Aquino R,Stepanchick E,Versele M,Liu Y,Yang J,Lu R,Balasubramanian S

    更新日期:2018-04-01 00:00:00

  • Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a s

    abstract::The HD-9 trial showed that eight cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine)-escalated led to significant improvements in response rate, progression-free survival and overall survival over COPP/ABVD (cyclophosphamide, vincristine, prednisone, procarbaz...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.975804

    authors: Belada D,Štěpánková P,Sýkorová A,Žák P,Smolej L

    更新日期:2015-07-01 00:00:00

  • Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.

    abstract::The prognostic significance of immunophenotype and other features including sex, age, anaemia, WBC, FAB type, and PAS staining were analysed in a group of 389 children newly diagnosed as acute lymphoblastic leukemia (ALL) and treated according to the BFM 1981/1983 protocol. The CR rate was higher (82-94%) in immunophe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209053627

    authors: Holowiecki J,Koehler M,Zintl Z,Kardos G,Lutz D,Krzemien S,Rewesz T,Brugiatelli M,Callea V,Kachel L

    更新日期:1992-06-01 00:00:00

  • Acute Megakaryoblastic Leukemia: Importance of Bone Marrow Biopsy in Diagnosis.

    abstract::Five cases of megakaryoblastic leukemia, presenting as "de novo" acute leukemias are reported. They represented 7.2% of all cases of adult acute non-lymphoblastic leukemias (ANLL) seen in our Hematology Service during the past 30 months. These cases showed features of predominantly blast proliferation with a marked in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109107060

    authors: Lorand-Metze I,Vassallo J,Aoki RY,De Souza CA

    更新日期:1991-01-01 00:00:00

  • Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.

    abstract::Chemotherapy has long been integral to the treatment of chronic lymphocytic leukemia (CLL). Fludarabine/cyclophosphamide, chlorambucil and bendamustine are commonly used as a backbone, depending on the patient's age and general health. The advent of the anti-CD20 monoclonal antibodies, such as rituximab and obinutuzum...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1330474

    authors: Wendtner CM,Gregor M

    更新日期:2018-02-01 00:00:00

  • Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis.

    abstract::Natural killer (NK) cells provide anti-infectious, anti-neoplastic, and immunomodulatory function effected by both cytokine production and direct cellular cytotoxicity that is not major histocompatibility complex-restricted. NK cells lack truly specific cell surface determinants as well as antigen-specific receptors. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057982

    authors: Morice WG,Leibson PJ,Tefferi A

    更新日期:2001-04-01 00:00:00